Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD boosted its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 10.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,422,729 shares of the company's stock after acquiring an additional 138,623 shares during the period. Price T Rowe Associates Inc. MD owned 2.96% of Mirum Pharmaceuticals worth $58,831,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Dark Forest Capital Management LP bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at $308,000. Harvest Investment Services LLC purchased a new stake in Mirum Pharmaceuticals in the fourth quarter worth $236,000. Hsbc Holdings PLC bought a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth $269,000. Tower Research Capital LLC TRC grew its holdings in shares of Mirum Pharmaceuticals by 260.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,112 shares of the company's stock worth $211,000 after purchasing an additional 3,694 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its position in Mirum Pharmaceuticals by 6.0% in the 4th quarter. MetLife Investment Management LLC now owns 24,085 shares of the company's stock valued at $996,000 after buying an additional 1,356 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on MIRM shares. HC Wainwright lifted their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a report on Friday, February 28th. Robert W. Baird lifted their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $58.20.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, SVP Jolanda Howe sold 57,606 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the sale, the senior vice president now directly owns 4,841 shares in the company, valued at approximately $214,698.35. This trade represents a 92.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Peter Radovich sold 2,627 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $126,673.94. Following the sale, the chief operating officer now owns 26,961 shares of the company's stock, valued at $1,300,059.42. This represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 105,557 shares of company stock valued at $4,726,040. Company insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Stock Performance

MIRM traded up $0.27 on Friday, hitting $43.69. 398,469 shares of the company traded hands, compared to its average volume of 519,728. The company has a 50 day moving average of $43.36 and a 200-day moving average of $44.07. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.83 and a 12-month high of $54.23. The stock has a market capitalization of $2.16 billion, a PE ratio of -21.63 and a beta of 1.00. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). The firm had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.